IL153439A0 - Medicines for the prevention and treatment of neurodegenerative diseases - Google Patents
Medicines for the prevention and treatment of neurodegenerative diseasesInfo
- Publication number
- IL153439A0 IL153439A0 IL15343901A IL15343901A IL153439A0 IL 153439 A0 IL153439 A0 IL 153439A0 IL 15343901 A IL15343901 A IL 15343901A IL 15343901 A IL15343901 A IL 15343901A IL 153439 A0 IL153439 A0 IL 153439A0
- Authority
- IL
- Israel
- Prior art keywords
- medicines
- prevention
- treatment
- neurodegenerative diseases
- neurodegenerative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000185814 | 2000-06-21 | ||
| PCT/JP2001/004934 WO2001098300A1 (fr) | 2000-06-21 | 2001-06-12 | Medicaments utilises dans la prevention et le traitement de maladies neurodegeneratives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL153439A0 true IL153439A0 (en) | 2003-07-06 |
Family
ID=18686074
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15343901A IL153439A0 (en) | 2000-06-21 | 2001-06-12 | Medicines for the prevention and treatment of neurodegenerative diseases |
| IL153439A IL153439A (en) | 2000-06-21 | 2002-12-15 | Drugs containing 3-oxadiazolyl-6,1-naphthyridine-2 (1H) - lozenges for the prevention and treatment of schizophrenia |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL153439A IL153439A (en) | 2000-06-21 | 2002-12-15 | Drugs containing 3-oxadiazolyl-6,1-naphthyridine-2 (1H) - lozenges for the prevention and treatment of schizophrenia |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6743803B2 (et) |
| EP (1) | EP1295883A4 (et) |
| KR (1) | KR20030010740A (et) |
| CN (1) | CN100354274C (et) |
| AU (2) | AU2001262741B2 (et) |
| BR (1) | BR0111799A (et) |
| CA (1) | CA2412199A1 (et) |
| CZ (1) | CZ20024153A3 (et) |
| EE (1) | EE04941B1 (et) |
| HU (1) | HUP0301319A3 (et) |
| IL (2) | IL153439A0 (et) |
| MX (1) | MXPA02012599A (et) |
| NO (1) | NO20026148L (et) |
| NZ (1) | NZ523189A (et) |
| PL (1) | PL200537B1 (et) |
| RU (1) | RU2258506C2 (et) |
| SK (1) | SK17682002A3 (et) |
| TW (1) | TWI298068B (et) |
| WO (1) | WO2001098300A1 (et) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6822097B1 (en) * | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
| TW200533371A (en) * | 2004-04-15 | 2005-10-16 | Dainippon Pharmaceutical Co | Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| WO2010002451A1 (en) * | 2008-07-01 | 2010-01-07 | Concert Pharmaceuticals, Inc. | Naphthyridin derivatives |
| JP6551671B2 (ja) * | 2015-08-11 | 2019-07-31 | 国立大学法人 熊本大学 | アルツハイマー治療薬 |
| MX2022000693A (es) * | 2019-07-18 | 2022-05-26 | Abaxys Therapeutics | Formulacion solida de un derivado de 1,2,4-oxadiazol. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2683818B1 (fr) | 1991-11-14 | 1993-12-31 | Adir Cie | Nouveaux derives de 3-sulfonylamino-2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| JPH09291034A (ja) | 1996-02-27 | 1997-11-11 | Yoshitomi Pharmaceut Ind Ltd | 縮合ピリジン化合物およびその医薬としての用途 |
| ZA985870B (en) * | 1997-07-15 | 1999-01-27 | Dainippon Pharmaceutical Co | 5-substituted-3-oxadiazolyl-1, 6-naphthyridin-2(1H)-one derivatives |
| AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| CH1196397H1 (de) | 1999-06-02 | 2007-05-31 | Nps Pharma Inc | Metabotrope Glutamatrezeptorantagonisten zur Behandlung von Krankheiten des zentralen Nervensystems. |
-
2001
- 2001-06-06 TW TW090113656A patent/TWI298068B/zh not_active IP Right Cessation
- 2001-06-12 US US10/311,932 patent/US6743803B2/en not_active Expired - Fee Related
- 2001-06-12 WO PCT/JP2001/004934 patent/WO2001098300A1/ja active IP Right Grant
- 2001-06-12 CZ CZ20024153A patent/CZ20024153A3/cs unknown
- 2001-06-12 AU AU2001262741A patent/AU2001262741B2/en not_active Ceased
- 2001-06-12 MX MXPA02012599A patent/MXPA02012599A/es active IP Right Grant
- 2001-06-12 CN CNB018142834A patent/CN100354274C/zh not_active Expired - Fee Related
- 2001-06-12 HU HU0301319A patent/HUP0301319A3/hu unknown
- 2001-06-12 CA CA002412199A patent/CA2412199A1/en not_active Abandoned
- 2001-06-12 EP EP01936958A patent/EP1295883A4/en not_active Withdrawn
- 2001-06-12 KR KR1020027017221A patent/KR20030010740A/ko not_active Application Discontinuation
- 2001-06-12 RU RU2003101405/04A patent/RU2258506C2/ru not_active IP Right Cessation
- 2001-06-12 BR BR0111799-8A patent/BR0111799A/pt not_active Application Discontinuation
- 2001-06-12 EE EEP200200698A patent/EE04941B1/et not_active IP Right Cessation
- 2001-06-12 PL PL363869A patent/PL200537B1/pl not_active IP Right Cessation
- 2001-06-12 SK SK1768-2002A patent/SK17682002A3/sk unknown
- 2001-06-12 IL IL15343901A patent/IL153439A0/xx active IP Right Grant
- 2001-06-12 NZ NZ523189A patent/NZ523189A/en unknown
- 2001-06-12 AU AU6274101A patent/AU6274101A/xx active Pending
-
2002
- 2002-12-15 IL IL153439A patent/IL153439A/en not_active IP Right Cessation
- 2002-12-20 NO NO20026148A patent/NO20026148L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL363869A1 (en) | 2004-11-29 |
| CZ20024153A3 (cs) | 2003-06-18 |
| TWI298068B (en) | 2008-06-21 |
| IL153439A (en) | 2007-07-24 |
| NO20026148D0 (no) | 2002-12-20 |
| AU2001262741B2 (en) | 2005-07-07 |
| US6743803B2 (en) | 2004-06-01 |
| EE200200698A (et) | 2004-08-16 |
| RU2258506C2 (ru) | 2005-08-20 |
| HUP0301319A2 (hu) | 2003-09-29 |
| SK17682002A3 (sk) | 2003-08-05 |
| AU6274101A (en) | 2002-01-02 |
| PL200537B1 (pl) | 2009-01-30 |
| EE04941B1 (et) | 2007-12-17 |
| CA2412199A1 (en) | 2001-12-27 |
| BR0111799A (pt) | 2003-05-27 |
| WO2001098300A1 (fr) | 2001-12-27 |
| EP1295883A4 (en) | 2003-06-11 |
| NO20026148L (no) | 2003-02-20 |
| HUP0301319A3 (en) | 2008-06-30 |
| EP1295883A1 (en) | 2003-03-26 |
| NZ523189A (en) | 2004-08-27 |
| MXPA02012599A (es) | 2003-05-14 |
| US20030166673A1 (en) | 2003-09-04 |
| CN1447809A (zh) | 2003-10-08 |
| KR20030010740A (ko) | 2003-02-05 |
| CN100354274C (zh) | 2007-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1399171A4 (en) | MEDICINAL HERB COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DIABETES | |
| IL196301A0 (en) | Medicament for the treatment of hapatitis c | |
| IL150742A0 (en) | Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease | |
| IL149924A0 (en) | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases | |
| GB2368794B (en) | Prevention and treatment of amyloidogenic disease | |
| HUP0301815A3 (en) | Mono and disaccharide-based pharmaceutical composition for infections and other diseases and prophylactic and therapeutic treatment | |
| EP1455778A4 (en) | METHODS OF TREATING PERIPHERAL NEUROVASCULAR MALAYS | |
| HUP0201205A2 (en) | Prevention and treatment of amyloidogenic disease | |
| HUP0400005A3 (en) | Use of osteopontin for the treatment and/or prevention of neurologic diseases | |
| EP1356278A4 (en) | METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING NEURODEGENERATIVE DISORDERS | |
| PL362920A1 (en) | Therapeutic film forming composition and treatment system | |
| GB0004531D0 (en) | The treatment of respiratory diseases | |
| HUP0400067A2 (hu) | Dementia és neurodegeneratív betegségek kezelése közepes dózisú LHRH-antagonistával | |
| EP1356812A4 (en) | DRUGS FOR TREATING AND PREVENTING NEUROLOGICAL PAIN | |
| IL153831A (en) | Pharmaceutical composition for therapy of neurodegenerative disease of the brain | |
| AU2002247973A1 (en) | Use of epigallocatechin-3-gallate or its derivatives in the prevention and treatment of neurodegenerative diseases | |
| HK1062810A1 (en) | Use of il-18 inhibitors for the manufacture of medicaments for treatment and/or prevention of heartdisease | |
| HUP0300402A3 (en) | Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them | |
| HUP0401913A3 (en) | Medicine for preventing and treating bromhidrosis | |
| AU6274101A (en) | Medicines for the prevention and treatment of neurodegenerative diseases | |
| AU2001262741A1 (en) | Medicines for the prevention and treatment of neurodegenerative diseases | |
| AU2001267165A1 (en) | Prevention and treatment of mycoplasma-associated diseases | |
| PL367634A1 (en) | Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases | |
| HUP0301847A3 (en) | Use of adatanserin for producing pharmaceutical compositions for the treatment and prevention of neurodegenerative conditions | |
| ZA200103250B (en) | The treatment of immunomodulatory related and other diseases or conditions. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |